EUVIMEDEUVIMED entdecken
Crossref

Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting

James S H Wong iD, Sarah Masson, Alan Huang, Deanna Romm, Maylene Fong, Tony Porter, Nader Sharifi, Pouya Azar, Nickie Mathew

Journal of Correctional Health Care · 01.12.2022 · 28 (6) · 368-371

DOI: 10.1089/jchc.21.07.0063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Correctional Health Care, erschienen am 01.12.2022. Verfasst von James S H Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Correctional Health Services, BC Mental Health and Substance Use Services, Provincial Health Services Authority, British Columbia, Canada. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incarcerated clients experience high rates of opioid use disorder and overdose. It is critical that opioid agonist treatment (OAT) is provided in correctional facilities. However, few receive OAT due to concerns about diversion, misuse, and safety. Buprenorphine extended-release (BUP-XR), a monthly buprenorphine depot injection, could be especially advantageous in the correctional setting as it can prevent diversion and misuse, saving staff resources and time. An injection of BUP-XR is costly compared with a monthly supply of buprenorphine/naloxone (BUP/NX) tablets. We demonstrate that when factoring in the added costs of medication preparation, administration, monitoring, and personnel, it is more economical to provide BUP-XR than BUP/NX. Other facilities, by utilizing our cost breakdown, can determine whether BUP-XR is economically advantageous at their own facility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersHumansNarcotic AntagonistsPrisonsBuprenorphine, Naloxone Drug CombinationTabletsCosts and Cost Analysis

Stichwörter der Autor:innen

buprenorphine extended-releasecost analysisjailsopioid agonist treatmentprisons

Substanzen

Narcotic AntagonistsBuprenorphine, Naloxone Drug CombinationBuprenorphineTablets

Autor:innen und Institutionen

  • Correctional Health Services, BC Mental Health and Substance Use Services, Provincial Health Services Authority, British Columbia, Canada.
  • Department of Psychiatry, University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Adult Custody Divisions, BC Corrections, Government of British Columbia, British Columbia, Canada.

ORCID-Profile: James S H Wong

Zitieren

APA

Wong, J. S. H., Masson, S., Huang, A., Romm, D., Fong, M., Porter, T., Sharifi, N., Azar, P., & Mathew, N. (2022). Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting. Journal of Correctional Health Care, 28(6), 368-371. https://doi.org/10.1089/jchc.21.07.0063

Vancouver

Wong JSH, Masson S, Huang A, Romm D, Fong M, Porter T, et al. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting. Journal of Correctional Health Care. 2022;28(6):368-371. doi:10.1089/jchc.21.07.0063

BibTeX
@article{Wong2022,
  author = {Wong, James S H and Masson, Sarah and Huang, Alan and Romm, Deanna and Fong, Maylene and Porter, Tony and Sharifi, Nader and Azar, Pouya and Mathew, Nickie},
  title = {Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting},
  journal = {Journal of Correctional Health Care},
  year = {2022},
  volume = {28},
  number = {6},
  pages = {368--371},
  doi = {10.1089/jchc.21.07.0063}
}
Kostenlos starten →